2013’s Expert Speaker Panel Features:
Implement the latest in-vitro and in-silico models and address the continual challenge of in-vitro to in-vivo extrapolation
The average cost of discovering and developing a drug now costs $900 million. With budget cuts hitting hard in the R&D field, it is imperative to validate the worth of predictive methods internally as they continue to facilitate the reduction in late stage drug attrition.
But the challenges remain: how do we cost-effectively develop and implement these in-vitro methods as accurately and as early in the drug discovery process as possible? How do we demonstrate the validation of these methods?
Pharma IQ brings together leading experts from across the industry, key regulatory bodies including the FDA and MHRA and leading consortia such as the IMI for the 5th Annual Predictive Toxicology Summit. Network with these industry leaders and learn how to:
- Implement the latest developments in predictive toxicology with crucial insight on the newest IMI projects from Maria Teresa de Magistris (IMI) complemented by the crucial new findings from Bayer and UCB pharma
- Cost-effectively integrate the latest predictive tools into established screening programmes with case studies from Jorrit Hornberg (Lundbeck)
- Successfully apply predictive toxicology in this complex regulatory environment with expertise from global regulators including MHRA and FDA
- Develop your processes and strategies with crucial cross industry expertise from Unilever as they share their expertise on non-animal approaches for predictive toxicology
- Validate the latest in-vivo, in-vitro and in-silico models with case studies from Astrazeneca, Johnson and Johnson and Ferrer Pharmaceuticals
Recent budget cuts are hitting the drug discovery and development field hard. Pharma IQ’s Creating Learner Strategies Session will help you to maximise your outputs, streamline your processes and reduce costs.
NEW FOR 2013: IN-VIVO FOCUS DAY
Identifying and implementing the best, most validated and predictive in-vivo derived models with expertise from Johnson and Johnson, Bayer and NC3R’s
This interactive, workshop based day focusses on the latest in-vivo techniques, models and strategic decision making process for those working in toxicology.
Discuss the successful positioning of models into already established programmes and best practices for cost effective integration of theses techniques. Hear from Johnson and Johnson on their latest transgenic models for liver toxicity. As well as expertise from the NC3R’s on implementing the 3R’s in toxicology.
Join this in-vivo focus day for the most up-to-date experiences and latest case studies in toxicology.
Interview with Vasily Dobrovolsky, Research Microbiologist, FDA
What People Have Said about the Predictive Toxicology Summit
“Overall very valuable, learning about new technology & forming partnerships to move the industry forward”AstraZeneca
“An excellent, informative conference as a refresher for current standing in predictive tox”Lonza Biologics
“Highly valuable and useful”Ferrer International